Back to School: How biopharma can reboot drug development. Access exclusive analysis here

EPS watch

EPS watch

EPS watch
United Therapeutics tacked on $619.3M, about 40%, in valuation last week after a double dose of good news. The company posted earnings that beat the Street concensus and reported that its Viveta met the primary endpoint in the Phase III TRIUMPH-1 trial to treat pulmonary arterial hypertension (PAH) (see "Phase III Reckoning," A16). Sepracor (SEPR) also enjoyed a double-digit percent jump last week on the heels of strong earnings and cost-cutting measures. Mcap in $M
Company 3Q07 EPS est 3Q07 EPS actual Outcome Growth from 3Q06 11/2 cls Wk chg % chg Mcap chg 11/2 Mcap

Read the full 1016 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers